Allergan plc (NYSE:AGN) Director Christopher J. Coughlin purchased 10,000 shares of Allergan stock in a transaction dated Thursday, September 6th. The shares were acquired at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NYSE AGN traded up $0.59 during mid-day trading on Friday, hitting $191.09. The stock had a trading volume of 6,430 shares, compared to its average volume of 1,544,225. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 0.85. Allergan plc has a twelve month low of $142.81 and a twelve month high of $237.41. The company has a market cap of $64.92 billion, a price-to-earnings ratio of 11.70, a PEG ratio of 1.47 and a beta of 1.21.
Allergan (NYSE:AGN) last released its earnings results on Thursday, July 26th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.13 by $0.29. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the prior year, the firm earned $4.02 EPS. The firm’s revenue was up 2.3% on a year-over-year basis. research analysts expect that Allergan plc will post 16.29 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, September 17th. Investors of record on Friday, August 17th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.51%. The ex-dividend date of this dividend is Thursday, August 16th. Allergan’s payout ratio is 17.61%.
AGN has been the topic of a number of recent analyst reports. Zacks Investment Research raised Allergan from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a research report on Wednesday, July 11th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Allergan in a research report on Tuesday, June 5th. Piper Jaffray Companies set a $161.00 price target on Allergan and gave the stock a “hold” rating in a research report on Thursday, May 31st. Cantor Fitzgerald set a $180.00 price target on Allergan and gave the stock a “hold” rating in a research report on Monday, June 11th. Finally, Credit Suisse Group set a $213.00 price target on Allergan and gave the stock a “buy” rating in a research report on Tuesday, June 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $210.10.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Edgewood Management LLC increased its position in shares of Allergan by 2.6% in the 2nd quarter. Edgewood Management LLC now owns 5,728,391 shares of the company’s stock valued at $955,037,000 after acquiring an additional 144,282 shares during the period. Franklin Resources Inc. grew its position in Allergan by 3.8% during the 1st quarter. Franklin Resources Inc. now owns 5,385,943 shares of the company’s stock worth $906,410,000 after purchasing an additional 198,257 shares during the period. Janus Henderson Group PLC grew its position in Allergan by 16.3% during the 2nd quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock worth $796,712,000 after purchasing an additional 668,343 shares during the period. The Manufacturers Life Insurance Company grew its position in Allergan by 1.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 4,254,493 shares of the company’s stock worth $715,989,000 after purchasing an additional 58,722 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Allergan by 2.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,545,557 shares of the company’s stock worth $591,116,000 after purchasing an additional 99,490 shares during the period. 77.37% of the stock is currently owned by hedge funds and other institutional investors.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Recommended Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.